GKT137831,
1218942-37-0,
GKT137831,
GKT-137831,
2-(2-Chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione,
Setanaxib,
UNII-45II35329V,
45II35329V,
AK134876,
2-(2-Chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo(4,3-c)pyridine-3,6(2H,5H)-dione,
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione,
GKT 137831,
setanaxib (proposed INN),
GKT831,
GTPL9932,
SCHEMBL1302603,
KS-00000RLK,
AOB5773,
DTXSID30153432,
EX-A577,
GKT-831,
BCP14159,
MFCD27923122,
s7171,
ZINC95670835,
AKOS022176138,
CS-3290,
SB19230,
NCGC00378460-08,
NCGC00378460-09,
BC600624,
HY-12298,
AJ-133482,
AX8256730,
ST2409276,
4CH-016131,
FT-0700121,
X3563,
A14433,
J-690070,
2-(2-Chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methylpyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione,
Abemaciclib,
D04XVU,
C21H19ClN4O2,
GKT-01,
RGYQPQARIQKJKH-UHFFFAOYSA-N,
C576694,
NADPH oxidase inhibitor (oral, renal cancer/ idiopathic pulmonary fibrosis), GenKyoTex,